Xtandi plus leuprolide improved overall survival in prostate cancer patients in the Phase 3 EMBARK trial, with no new safety ...

J&J is looking to add a hormone-sensitive indication to its prostate cancer therapy, which was originally approved in 2023.

J&J has rights to niraparib in prostate cancer, and views the drug as a successor to Zytiga, once a $2.5 billion-a-year ...

Grail announced that results from the registrational PATHFINDER 2 study of its Galleri multi-cancer early detection test showed that adding the test to standard-of-care screening resulted in ...

FDA approves updated labeling for Talzenna plus Xtandi in men with HRR gene-mutated metastatic prostate cancer, showing a 14-month survival benefit.

Despite recent declines, we believe Pfizer stock is a compelling buy right now, with its current price of around $23 likely reflecting existing concerns.

FDA advisors unanimously snub Pfizer's Talzenna in broader prostate cancer population FDA advisors unanimously voted against expanding Pfizer’s Talzenna to a broader prostate cancer population without ...

Pfizer Inc. failed to convince advisers to the US Food and Drug Administration to support a dramatic expansion in the use of its prostate cancer drug, a setback that could scuttle the company’s ...

Pfizer exits Sanford, North Carolina jobs deal after Abzena acquisition. Drugmaker cites economic climate for not meeting Lee County hiring and investment goals.

The report said GSK’s former head of vaccine development, Philip Dormitzer, who joined the company after working at rival Pfizer, had told his GSK colleagues about the delay.